Milestone Pharmaceuticals Inc.

$0.92Close · Sep 22, 2026

News

Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial – The Lancet
Jun 20, 2023Milestone Pharma
The post Self-administered intranasal etripamil using a symptom-prompted, repeat-dose regimen for atrioventricular-nodal-dependent supraventricular tachycardia (RAPID): a multicentre, randomised trial – The Lancet appeared first on Milestone Pharma.
Impact of Investigational, at-Home, Self-administered, Intranasal Etripamil on the Need for Additional Medical Intervention in Patients With Supraventricular Tachycardia
May 31, 2023Milestone Pharma
The post Impact of Investigational, at-Home, Self-administered, Intranasal Etripamil on the Need for Additional Medical Intervention in Patients With Supraventricular Tachycardia appeared first on Milestone Pharma.
Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Presentation
May 26, 2023Milestone Pharma
The post Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Presentation appeared first on Milestone Pharma.
Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Poster
May 26, 2023Milestone Pharma
The post Effect of Etripamil Nasal Spray on Ventricular Rate in Patients Experiencing Symptomatic Atrial Fibrillation: Poster appeared first on Milestone Pharma.
Potential New Therapeutic Option for the Treatment of SVT in Acute and Chronic Settings
May 4, 2023Milestone Pharma
News in SVT Diagnosis and Management A. John Camm 16th April 2023 EHRA 2023 The post Potential New Therapeutic Option for the Treatment of SVT in Acute and Chronic Settings appeared first on Milestone Pharma.
First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301)
Feb 28, 2023Milestone Pharma
The post First Randomized, Multicenter, Placebo-Controlled Study of Self-Administered Intranasal Etripamil for Acute Conversion of Spontaneous Paroxysmal Supraventricular Tachycardia (NODE-301) appeared first on Milestone Pharma.
Self-administered Etripamil for Termination of Spontaneous Paroxysmal Supraventricular Tachycardia: Primary Analysis from the RAPID Study
Nov 7, 2022Milestone Pharma
The post Self-administered Etripamil for Termination of Spontaneous Paroxysmal Supraventricular Tachycardia: Primary Analysis from the RAPID Study appeared first on Milestone Pharma.
Long-Term Outcomes of the NODE-302 Study. In the NODE-302 trial, the commonly recorded adverse events were nasal discomfort, nasal congestion, rhinorrhea, epistaxis, sneezing, cough, throat irritation, headache, and increased lacrimation. These adverse events were local and transient.
Oct 3, 2022Milestone Pharma
The post Long-Term Outcomes of the NODE-302 Study. In the NODE-302 trial, the commonly recorded adverse events were nasal discomfort, nasal congestion, rhinorrhea, epistaxis, sneezing, cough, throat irritation, headache, and increased lacrimation. These adverse events were local and transient. appeared first on Milestone Pharma.
Rationale for and design of a multicenter, placebo-controlled, phase 3 study to assess efficacy and safety of intranasal etripamil for the conversion of paroxysmal supraventricular tachycardia
Sep 20, 2022Milestone Pharma
The post Rationale for and design of a multicenter, placebo-controlled, phase 3 study to assess efficacy and safety of intranasal etripamil for the conversion of paroxysmal supraventricular tachycardia appeared first on Milestone Pharma.
Very Low Efficacy of Vagal Maneuvers in Terminating Paroxysmal Supraventricular Tachycardia: Results From the NODE-301 Study
May 4, 2022Milestone Pharma
The post Very Low Efficacy of Vagal Maneuvers in Terminating Paroxysmal Supraventricular Tachycardia: Results From the NODE-301 Study appeared first on Milestone Pharma.